Novel RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases

ACS Med Chem Lett. 2022 Mar 2;13(4):524-525. doi: 10.1021/acsmedchemlett.2c00059.

Ram W Sabnis ¹

Affiliations

Affiliation

1 Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia30309, United States.

PMID: 35450352 DOI: 10.1021/acsmedchemlett.2c00059

Products

Cat. No.

Product Name

Description

Target

Research Area
HY-143480

RIPK1-IN-15

RIPK1 Inhibitor

RIP kinase

Neurological Disease; Inflammation/Immunology

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator

Subscribe to our E-newsletter

Name
Email *

	Sorry, but the email address you supplied was invalid.

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2024 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us